



UNIVERSITY OF LEEDS

This is a repository copy of *Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/169834/>

Version: Accepted Version

Article:

Ager, M, Njoku, K, Serra, M et al. (12 more authors) (2020) Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. *BJU International*. ISSN 1464-4096

<https://doi.org/10.1111/bju.15309>

© 2020 The Authors *BJU International* © 2020 *BJU International* Published by John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Ager, M, Njoku, K, Serra, M et al. (12 more authors) (2020) Long-term multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. *BJU International*. ISSN 1464-4096, which has been published in final form at <http://doi.org/10.1111/bju.15309>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Tables 1 to 5:

Table 1: Patient,centre, node and treatment characteristics

	Total n (%)	Adjuvant Radiotherapy		
		Completed	Stopped	Not given
Patients n	146	121 (82.9)	4 (2.7)	21 (14.4)
St George's	73	61 (83.6)	4 (5.5)	8 (10.9)
Leeds	73	60 (82.2)	0	13 (17.8)
Age, median (IQR)	59 (54 -70)	59 (52 - 68)	64 (59 – 69)	62 (57 – 76)
Chemo sensitisation				
Yes	60 (41.1)	59 (48.8)	1 (25)	-
No	72 (49.3)	50 (41.3)	1 (25)	21 (100)
*	14 (9.6)	12 (9.9)	2 (50)	-
pN3				
iENE only	108	86 (79.6)	2 (1.9)	20 (18.5)
<u>iENE and pENE</u>	36	33 (91.7)	2 (5.6)	1 (2.7)
Inguinal pN2, pelvic	2	2 (100)	0	0
pN3 without ENE				
iLND				
Yes	146 (100)	121 (82.9)	4 (2.7)	21 (14.4)
pLND				
Yes	75 (51.4)	70 (57.9)	2 (50)	3 (14.3)
No	71 (48.6)	51 (42.1)	2 (50)	18 (85.7)

No. positive nodes				
median (IQR)				
Inguinal	2 (1-3)	-	-	-
Pelvic	1 (1-2)	-	-	-
Radiotherapy				
> 50Gy	60 (49.6)	60 (49.6)	-	-
< 50Gy	49 (40.5)	49 (40.5)	-	-
*	12 (9.9)	12 (9.9)	-	-

IQR – interquartile range, iLND – inguinal lymphadenectomy, pLND – pelvic

lymphadenectomy, iENE – inguinal extranuclear extension, pENE – pelvic extranuclear

extension, * missing data.

Table 2: Systemic agents used for chemoradiotherapy

CHEMOTHERAPY	NO. OF PATIENTS WHO RECEIVED
PLATINUM BASED	42 (33.6)
NO CHEMOTHERAPY	54 (43.2)
CAPECITABINE	1 (0.8)
5FU + MMC	4 (3.2)
NOT DEFINED	24 (19.2)
TOTAL	125 (100)

Table 3: Nodal stations of radiotherapy delivery and number of patients with recurrence in the irradiated site

NODAL STATIONS OF ADJUVANT THERAPY	NO. OF PATIENTS	NO. OF PATIENTS WITH IN-FIELD RECURRENCE
UNILATERAL INGUINAL ONLY	19	3 (2.4)
UNILATERAL INGUINAL AND PELVIS	40	10 (8.0)
BILATERAL INGUINAL ONLY	5	1 (0.8)
BILATERAL INGUINAL AND UNILATERAL PELVIS	2	0 (0)
BILATERAL INGUINAL AND PELVIS	44	12 (9.5)
HAD RADIOTHERAPY BUT NODAL STATION NOT SPECIFIED	15	Unknown
TOTAL	125	26 (20.8)

Table 4: Sites of recurrence

SITE OF RECURRENCE	NO. OF PATIENTS
INGUINAL ONLY	20 (30.9)
PELVIC ONLY	7 (12.7)
INGUINAL AND PELVIC	3 (5.5)
PELVIC AND LUNG	1 (1.8)
LUNG	13 (23.6)
INGUINAL AND LUNG	3 (5.5)
INGUINAL, PELVIC AND LUNG	2 (3.6)
OTHER SITES (RETROPERITONEAL / PARA-AORTIC/ CUTANEOUS)	6 (10.9)

TOTAL	55
--------------	----

Table 5: Radiotherapy dose and fractions

NO. OF PATIENTS	DOSE (GY)	FRACTIONS (#)
28	46	23
23	45	20
15	60	30
11	54	27
9	50	25
<u>23</u>	<u>Other fractionations</u>	
7	45	20
5	50.4	28
2	54	30
2	55	20
1	56	32
1	65	28
1	58	24
1	54	25
1	60.4	33
1	46	20
1	40	20